Connor, Clark & Lunn Investment Management (CC&L)’s Impax Laboratories, Inc. IPXL Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-39,100	Closed	-$927K	–	671
2014 Q3	$927K	Sell	39,100 -5,100	-12%	-$131K	0.01%	315
2014 Q2	$1.41M	Sell	44,200 -65,700	-60%	-$1.77M	0.01%	280
2014 Q1	$3.21M	Buy	109,900 +35,800	+48%	+$895K	0.02%	213
2013 Q4	$1.98M	Buy	74,100 +35,400	+91%	+$790K	0.02%	266
2013 Q3	$814K	Buy	+38,700	New	+$799K	0.01%	289

Other funds holding IPXL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s IPXL Position: Q4 2014 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Impax Laboratories, Inc. (IPXL) in Q4 2014, closing a stake of 39,100 shares — an estimated $927K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in IPXL in Q3 2013 and held it in 5 quarters. The position peaked at $3.21M in Q1 2014. 178 funds tracked by Wall St. Rank hold IPXL as of Q4 2014.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Impax Laboratories, Inc. position as of Q4 2014 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 39,100 Impax Laboratories, Inc. shares in Q4 2014, an estimated $927K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Impax Laboratories, Inc. in Q3 2013 and held it in 5 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Impax Laboratories, Inc. position peaked at $3.21M in Q1 2014.
178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2014.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2014, filed 12 Feb 2015.